Pipeline

Our focus on and deep understanding of the biology and Mechanism of Action of the CD40 Ligand have driven Eledon’s research and development of our lead product candidate tegoprubart. Extensive preclinical and clinical stage research demonstrates that tegoprubart effectively targets the CD40L pathway, which plays a central role in organ rejection. Eledon is currently conducting clinical research on the potential benefits of treatment with tegoprubart in kidney transplantation, islet cell transplantation and xenotransplantation.

The company is also assessing the benefits of targeting the CD40L in patients with autoimmune and neurodegenerative diseases including ALS. Eledon has successfully completed a Phase 2, dose ranging, biomarker study in ALS.

Indications	Preclinical	Phase 1¹	Phase 2	Phase 3	Notes
Allotransplantation
Kidney					Phase 2 BESTOW trial completed Phase 1b & Long-Term Extension trials ongoing
Islet Cell					Eledon and investigator-sponsored trials Received U.S. FDA Orphan Drug Designation
Kidney Tolerance Induction					Mass. Gen. Hospital investigator-led study
Liver					IND-ready Received U.S. FDA Orphan Drug Designation
Xenotransplantation
Kidney					Performed under U.S. FDA Expanded Access Protocol (EAP) eGenesis sponsored Phase 1/2/3 study
Adult Heart					Performed under U.S. FDA Expanded Access Protocol (EAP)
Pediatric Heart
Amyotrophic Lateral Sclerosis (ALS) ²					Completed Phase 2 trial

Allotransplantation
Kidney
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Phase 2 BESTOW trial completed Phase 1b & Long-Term Extension trials ongoing
Islet Cell
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Eledon and investigator-sponsored trials Received U.S. FDA Orphan Drug Designation
Kidney Tolerance Induction
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Mass. Gen. Hospital investigator-led study
Liver
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

IND-ready Received U.S. FDA Orphan Drug Designation
Xenotransplantation
Kidney
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Performed under U.S. FDA Expanded Access Protocol (EAP) eGenesis sponsored Phase 1/2/3 study
Adult Heart
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Performed under U.S. FDA Expanded Access Protocol (EAP)
Pediatric Heart
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes


Amyotrophic Lateral Sclerosis (ALS) ²
Preclinical	Phase 1¹	Phase 2	Phase 3	Notes

Completed Phase 2 trial

Note: As of June 2026. Development plans and timelines may change, including based on U.S. and global regulatory interactions.
1. Inclusive of early human trials
2. Seeking non-equity dilutive financing to advance program to Phase 3